Cannabinoids and Anxiety-related outcomes

In a phase 2 randomized double-masked placebo-controlled clinical trial involving 50 women with advanced breast cancer and baseline clinical anxiety, researchers did not detect a difference in pre-to-post scan-related anxiety change score following 400 mg once by the oral route over single dose with assessment 2 to 4 hours later. The recorded comparator was placebo. ²

Recorded result: Mean change was -19.1 (SD 15.4) with CBD and -15.0 (SD 10.9) with placebo; P=0.37.

In a phase 2 randomized double-masked placebo-controlled clinical trial involving 50 women with advanced breast cancer and baseline clinical anxiety, researchers reported a decrease in scan-related anxiety level 2 to 4 hours after dosing following 400 mg once by the oral route over single dose with assessment 2 to 4 hours later. The recorded comparator was placebo. ²

Recorded result: Mean T-score was 51.5 (SD 12.8) with CBD and 58.0 (SD 11.6) with placebo; P=0.02.

In a randomized double-blind placebo-controlled four-arm trial involving 57 healthy male volunteers, researchers reported a decrease in public-speaking anxiety after 300 mg CBD in healthy volunteers following 300 mg once by the oral route over single dose before a simulated public-speaking test. The recorded comparator was placebo. ³

Recorded result: The 300 mg group had significantly lower speech-related anxiety than placebo; the abstract provides no effect estimate or P value.

In a randomized double-blind placebo-controlled four-arm trial involving 57 healthy male volunteers, researchers did not detect a difference in public-speaking anxiety after 150 mg or 600 mg cbd in healthy volunteers following 150 mg or 600 mg once by the oral route over single dose before a simulated public-speaking test. The recorded comparator was placebo. ³

Recorded result: Neither 150 mg nor 600 mg differed significantly from placebo on VAMS anxiety scores.

In a randomized double-blind placebo-controlled parallel trial involving 24 treatment-naive patients with social anxiety disorder plus 12 untreated healthy controls, researchers reported a decrease in public-speaking anxiety in treatment-naive social anxiety disorder following 600 mg once by the oral route over single dose 90 minutes before a simulated public-speaking test. The recorded comparator was placebo; untreated healthy-control reference group. ⁴

Recorded result: CBD significantly reduced speech-related anxiety; the abstract provides no effect estimate or P value.

In a randomized double-blind placebo-controlled parallel trial involving 24 treatment-naive patients with social anxiety disorder plus 12 untreated healthy controls, researchers reported a decrease in public-speaking cognitive impairment and discomfort in social anxiety disorder following 600 mg once by the oral route over single dose 90 minutes before a simulated public-speaking test. The recorded comparator was placebo; untreated healthy-control reference group. ⁴

Recorded result: CBD significantly reduced cognitive impairment and discomfort during speech performance; numerical estimates were not reported in the abstract.

In a randomized double-blind placebo-controlled clinical trial involving patients undergoing endodontic treatment; sample size not stated in the PubMed abstract, researchers did not detect a difference in reduction in procedural dental anxiety following not stated in the PubMed abstract by the oral route over single preoperative administration with follow-up through 7 days. The recorded comparator was placebo. ⁵

Recorded result: Mean anxiety was 5.06 before and 4.61 after treatment with the extract versus 3.07 and 2.60 with placebo; reduction did not differ significantly.

In a randomized double-blind placebo-controlled crossover trial involving 24 people with Parkinson's disease, researchers reported a decrease in public-speaking anxiety in people with Parkinson's disease following 300 mg once by the oral route over two experimental sessions separated by 15 days. The recorded comparator was placebo. ⁶

Recorded result: CBD significantly attenuated experimentally induced anxiety; the abstract provides no effect estimate or P value.

In a randomized double-blind placebo- and active-comparator trial involving 40 healthy volunteers across four groups, including 10 assigned to CBD, researchers reported a decrease in anxiety after simulated public speaking in healthy volunteers following 300 mg once by the oral route over single experimental session. The recorded comparator was placebo, diazepam, and ipsapirone groups. ⁷

Recorded result: CBD decreased anxiety after the speaking test; the abstract provides no effect estimate or P value.

In a phase 3 multicenter randomized double-blind placebo-controlled parallel trial involving 178 participants in India with mild-to-moderate anxiety disorders, researchers reported a decrease in Generalized Anxiety Disorder-7 score following not stated in the PubMed abstract by the oral route over 15 weeks. The recorded comparator was placebo. ⁸

Recorded result: CBD-versus-placebo end-to-baseline difference -7.02 (SE 0.25; 95% CI -7.52 to -6.52; P<0.0001).

In a phase 3 multicenter randomized double-blind placebo-controlled parallel trial involving 178 participants in India with mild-to-moderate anxiety disorders, researchers reported a decrease in Hamilton Anxiety Rating Scale score following not stated in the PubMed abstract by the oral route over 15 weeks. The recorded comparator was placebo. ⁸

Recorded result: CBD-versus-placebo end-to-baseline difference -11.9 (SE 0.33; 95% CI -12.6 to -11.3; P<0.0001).

In a systematic review and meta-analysis involving 316 participants across eight studies involving anxiety-related conditions, researchers reported a decrease in pooled anxiety symptoms across CBD studies following varied across included studies by the oral route over varied across included studies. The recorded comparator was varied across included studies. ⁹

Recorded result: Pooled Hedges' g was -0.92 (95% CI -1.80 to -0.04) in favor of CBD.

In an open-label add-on trial involving 31 people aged 12 to 25 years with treatment-resistant anxiety disorders, researchers reported a decrease in within-group anxiety severity following fixed-flexible schedule titrated up to 800 mg/day by the not stated in the PubMed abstract route over 12 weeks. The recorded comparator was none; within-group baseline comparison. ¹⁰

Recorded result: Mean OASIS decreased from 10.8 (SD 3.8) to 6.3 (SD 4.5), a 42.6% within-group reduction (P<0.0001).

In an open-label add-on trial involving 31 people aged 12 to 25 years with treatment-resistant anxiety disorders, researchers reported a decrease in within-group depressive symptoms following fixed-flexible schedule titrated up to 800 mg/day by the not stated in the PubMed abstract route over 12 weeks. The recorded comparator was none; within-group baseline comparison. ¹⁰

Recorded result: Depressive symptoms improved within the open-label group (P<0.0001); the abstract provides no effect estimate.

In an open-label add-on trial involving 31 people aged 12 to 25 years with treatment-resistant anxiety disorders, researchers reported a decrease in within-group Clinical Global Impressions severity score following fixed-flexible schedule titrated up to 800 mg/day by the not stated in the PubMed abstract route over 12 weeks. The recorded comparator was none; within-group baseline comparison. ¹⁰

Recorded result: CGI-Severity improved within the open-label group (P=0.0008); the abstract provides no effect estimate.

In an open-label add-on trial involving 31 people aged 12 to 25 years with treatment-resistant anxiety disorders, researchers reported an increase in within-group social and occupational functioning following fixed-flexible schedule titrated up to 800 mg/day by the not stated in the PubMed abstract route over 12 weeks. The recorded comparator was none; within-group baseline comparison. ¹⁰

Recorded result: Functioning improved within the open-label group (P=0.04); the abstract provides no effect estimate.